LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

About this update from Lenz Therapeutics, Inc.

Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO , June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader (“KOL”) event on Tuesday, June 18, 2024 at 8:00 a.m. ET . The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectives on LNZ100 data from the Phase 3 CLARITY study. The event will feature presentations by Eef Schimmelpennink, Chief Executive Officer, Marc Odrich , M.D., Chief Medical Officer, and the following guest speakers: Jason Bacharach , M.D. Dr. Bacharach is the Founding Partner as well as Medical & Research Director of North Bay Eye Associates, Inc. He has been a primary investigator in over 200 phase I through IV clinical trials in Ophthalmology. He is the former Chair of the American Academy’s Ophthalmic Knowledge Based Panel for Glaucoma and serves as a board examiner for the American Board of Ophthalmology . Lastly, he has been honored with an Achievement Award in 2005 and the Secretariat Award in 2013 from the American Academy of Ophthalmology . Dr. Bacharach was a Principal Investigator in the CLARITY Phase 3 study. Marc Bloomenstein , O.D. Dr. Bloomenstein is the Director of Optometric Services at the Schwartz Laser Eye Center in Scottsdale, Arizona . He is a Chairman of the Education Committee for Vision Expo , AOA CE Committee and served on the board of the Ocular Surface Society of Optometry (OSSO), as well as a founding member of the Optometric Cornea, Cataract, and Refractive Society (OCCRS). Dr. Bloomenstein was a Principal Investigator in the CLARITY Phase 3 study. Milton Hom , O.D. Dr. Hom is an internationally recognized expert and researcher in therapeutics, dry eye, presbyopia, contact lenses, and allergy. He is also co-medical director for the multi-site Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA) study. Dr. Hom has authored 4 books and published over 200 papers and peer-reviewed abstracts. Dr. Hom was a Principal Investigator in the CLARITY Phase 3 study. A live question and answer session will follow the formal presentations. A live webcast of the KOL event will be available and those who intend to join virtually can pre-register for the webcast through the link here . Supporting presentation materials will be available on the Events section of the Investor Relations page of the LENZ Therapeutics website at ir.LENZ-tx.com at the time of the live event. An archived replay of the webcast will be available on the Company’s website. About LENZ Therapeutics LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States . LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California . For more information, visit: LENZ-Tx.com . Contacts: Dan Chevallard LENZ Therapeutics, Inc. [email protected] Source: LENZ Therapeutics, Inc.

View stock analysis, news, and events for Lenz Therapeutics, Inc.